How is Family-Owned Biotech Disrupting Traditional Pain Management Solutions?

Key Takeaways:

• The Grunenthal Group is an independent, family-owned, international research-based pharmaceutical company, based in Germany, operating in 25 countries globally.
• Invests a significant portion (27%) of its revenues back into research and development, focusing on innovations in pain management.
• Has the constant objective of becoming the most patient-centric company in the field of pain management.
• The company differentiates itself with its intense focus on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

As the medical world evolves, so does the approach to managing pain. One company leading this evolution is the Germany-based Grunenthal Group. As a family-owned, independent, research-based pharmaceutical enterprise, the Grunenthal Group is making significant strides in disrupting traditional pain management solutions. With operations in 25 countries and its products being sold in over 155 countries, the Grunenthal Group’s global reach demonstrates its commitment to innovative pain management solutions.

The Grunenthal Group is dedicated to becoming the most patient-centric company in the field of pain. It consistently invests in research and development, with about 27 percent of its revenues in 2013 being directed towards this cause. The company’s principle focus is on specific fields of therapy and cutting-edge technologies in an effort to deliver the best possible patient outcomes.

The Grunenthal Group’s unique approach to pain management sets it apart in the biotech industry. The company’s intense focus on discovering new ways to treat pain far more effectively and with fewer side-effects than current therapies represents a significant shift from traditional pain management solutions. This uncompromising focus on innovation and patient-centricity makes the Grunenthal Group a game-changer in the realm of pain management.

Moreover, the Grunenthal Group’s sustainable investment in research and development sets it apart as one of the handful of research-oriented pharmaceutical companies in Germany, and boosts its credibility within the industry and among patients alike. This commitment underscores the company’s dedication to revolutionising the treatment of pain and underscores the importance of research and patient-centricity to its overall approach.

The future appears bright for the Grunenthal Group. With their steady dedication to patient-focused innovation, the company is likely to continue disrupting traditional pain management solutions. Further, the impact of the Grunenthal Group is likely to reverberate throughout the industry, forcing competitors to ramp up their own research and development efforts and reshaping the field of pain management as a whole. To follow their progress and stay updated, you can check their official website, and follow them on Twitter, Facebook and LinkedIn.

Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!